November 1, 2023 03:09 PM EDT
Pharma
FDA+

No­var­tis scores sixth Cosen­tyx ap­proval from FDA, this time to treat hidradeni­tis sup­pu­ra­ti­va

Lia DeGroot

No­var­tis on Tues­day nabbed an­oth­er in­di­ca­tion for its bi­o­log­ic Cosen­tyx (se­cuk­inum­ab), this time in the grow­ing field of treat­ments tar­get­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

#JPM25 live blog day 1: How will Trump 2.0 im­pact the bio­phar­ma in­dus­try? Scott Got­tlieb, Bob Nelsen share ...

A service from the Financial Times